Instil Bio reports Q1 2026 cash of $74.7M, GAAP net loss per share $0.62

Instil Bio, Inc.

2026-Q1 EPS reported -$0.62

Cash, equivalents, restricted cash and marketable securities $74.7M as of March 31, 2026; expected to fund operations beyond 2027.
GAAP net loss per share $0.62; non-GAAP net loss per share $0.32 for Q1 2026.
R&D expenses $0.7M (down from $5.4M YoY); G&A expenses $5.3M (down from $9.1M).
Company actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.